OREXO AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.65 USD | +17.86% |
|
-.--% | +9.27% |
| May. 08 | Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024 | |
| Apr. 17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Specialty & Advanced Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 78.51B | ||||||
| 9B | ||||||
| 4.96B | - | - | ||||
| 4.84B | ||||||
| 3.72B |
- Stock Market
- Equities
- ORX Stock
- ORXOY Stock
- Charts Orexo AB
- Sector Chart
